Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $47.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments